HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women.

AbstractOBJECTIVES:
To assess the effects of Femoston (2 mg micronised 17 beta oestradiol daily, sequentially combined in one tablet with 10 mg dydrogesterone for 14 days per 28 day cycle) on the serum lipid profile of postmenopausal women.
METHODS:
188 healthy postmenopausal women with intact uteri (aged 40 to 65 years) were enrolled in an open, multicentre, one-year study. Serum lipids and lipoproteins were measured at baseline and after 3, 6 and 12 months.
RESULTS:
A total of 155 women completed the one-year study. Mean serum levels of total cholesterol and low-density lipoprotein (LDL)-cholesterol were significantly reduced (P < 0.01) at all assessments compared with baseline; the reductions observed at the final assessment were 5 and 20%, respectively. A significant increase of 20% (P < 0.01) was seen in high-density lipoprotein (HDL)-cholesterol levels by month 12. Mean levels of triglycerides were also increased (p < 0.01). Blood pressure and heart rate remained unchanged throughout the study.
CONCLUSIONS:
The results show that the overall effects of Femoston on the serum lipid profile are comparable to those found with oestrogen therapy alone and should reduce the risk of cardiovascular disease in postmenopausal women.
AuthorsM Gelfand, P Fugère, F Bissonnette
JournalMaturitas (Maturitas) Vol. 26 Issue 2 Pg. 125-32 (Mar 1997) ISSN: 0378-5122 [Print] Ireland
PMID9089562 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Drug Combinations
  • Lipids
  • Lipoproteins
  • Progesterone Congeners
  • Tablets
  • Triglycerides
  • Estradiol
  • Dydrogesterone
  • Cholesterol
Topics
  • Adult
  • Aged
  • Blood Pressure
  • Cholesterol (blood)
  • Cholesterol, HDL (blood)
  • Cholesterol, LDL (blood)
  • Drug Combinations
  • Dydrogesterone (administration & dosage, therapeutic use)
  • Estradiol (administration & dosage, therapeutic use)
  • Estrogen Replacement Therapy
  • Female
  • Follow-Up Studies
  • Heart Diseases (etiology)
  • Heart Rate
  • Humans
  • Lipids (blood)
  • Lipoproteins (blood)
  • Middle Aged
  • Postmenopause (blood)
  • Progesterone Congeners (administration & dosage, therapeutic use)
  • Risk Factors
  • Tablets
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: